Penserra Capital Management LLC Invests $2.35 Million in ADMA Biologics, Inc. (NASDAQ:ADMA)

Penserra Capital Management LLC purchased a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 117,581 shares of the biotechnology company's stock, valued at approximately $2,350,000. Penserra Capital Management LLC owned approximately 0.05% of ADMA Biologics at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ADMA. Bank of Montreal Can acquired a new stake in ADMA Biologics during the 2nd quarter worth $17,886,000. D. E. Shaw & Co. Inc. boosted its stake in ADMA Biologics by 26.8% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company's stock worth $76,298,000 after purchasing an additional 1,442,799 shares during the period. Principal Financial Group Inc. increased its holdings in ADMA Biologics by 785.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company's stock worth $23,872,000 after purchasing an additional 1,059,394 shares in the last quarter. Castleark Management LLC bought a new position in ADMA Biologics during the 1st quarter worth about $5,400,000. Finally, First Turn Management LLC acquired a new stake in shares of ADMA Biologics in the 3rd quarter valued at about $13,293,000. Institutional investors own 75.68% of the company's stock.

Analyst Upgrades and Downgrades

ADMA has been the topic of several research reports. HC Wainwright boosted their target price on ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, November 8th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th. Finally, Raymond James boosted their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research report on Friday, November 8th.

ADMA Biologics Stock Performance

ADMA stock traded up $0.35 during trading hours on Tuesday, reaching $21.82. The stock had a trading volume of 1,827,884 shares, compared to its average volume of 3,624,915. The stock has a 50-day simple moving average of $18.92 and a 200 day simple moving average of $15.05. ADMA Biologics, Inc. has a fifty-two week low of $3.60 and a fifty-two week high of $23.64. The stock has a market capitalization of $5.16 billion, a PE ratio of 77.04 and a beta of 0.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The business had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. During the same period last year, the business posted $0.01 EPS. Analysts predict that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Insider Activity

In other news, Director Lawrence P. Guiheen sold 9,000 shares of the firm's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the sale, the director now directly owns 153,941 shares of the company's stock, valued at $2,843,290.27. This trade represents a 5.52 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Jerrold B. Grossman sold 136,861 shares of the firm's stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $17.27, for a total value of $2,363,589.47. Following the completion of the sale, the director now directly owns 467,305 shares of the company's stock, valued at approximately $8,070,357.35. The trade was a 22.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 185,011 shares of company stock valued at $3,255,204 over the last three months. Insiders own 3.70% of the company's stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.